Site Search

Press Releases

Investor Relations

Normal

Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015

February 27, 2023

Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update

Download PDF format download (opens in new window)

January 31, 2023

Aptinyx to Present at the SVB Securities Global Biopharma Conference

Download PDF format download (opens in new window)

Quick Links

Press Releases
Events & Presentations
Stock Information

IR Contact

ir@aptinyx.com
847-871-0377

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Aptinyx Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Aptinyx Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Mailing Lists *

News
Events & Presentations
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote

Unsubscribe